Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nipah virus mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- Vernagen
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Nipah virus mRNA vaccine is an engineered mRNA-based vaccine being developed by Vernagen, in collaboration with Duke-NUS Medical School, for the prevention of Nipah virus infection. The vaccine utilizes lipid nanoparticle (LNP) delivery technology to deliver messenger RNA encoding Nipah virus antigens, specifically the soluble Nipah virus glycoprotein (soluble NiV-G) fused with a human collagen type I alpha 1 (COL1A1) signal peptide, full-length Nipah virus glycoprotein (full-length NiV-G), and/or full-length Nipah virus fusion protein (full-length NiV-F). Upon administration, the vaccine induces a protective immune response, including neutralizing antibodies, against the Nipah virus. It is currently in preclinical development.
- Other names
- engineered nipah virus mRNA vaccine
02
Targets
NiV-F (Nipah virus fusion glycoprotein)EFNB2 (Ephrin-B2)EPH (EPH receptor family)NiV-G (Nipah virus attachment glycoprotein)
Beyond the preview
Go deeper on nipah virus mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nipah virus mRNA vaccine.